WASHINGTON, January 25, 2023 /PRNewswire/ — The LUNGevity Foundation is partnering with the American Society for Radiation Oncology (ASTRO), the world’s largest radiation oncology society, to support radiation oncology research — an important area of study for early detection and lung cancer treatment.
“Radiation oncology plays a central role in the treatment of lung cancer, regardless of disease stage and histology,” he explained. Upal Basu Roy, PhD, MPH, Executive Director of Research at LUNGevity. “More than 60% of patients diagnosed with lung cancer will receive at least some form of radiotherapy with curative or palliative intent. We are pleased to partner with ASTRO due to our joint commitment to supporting junior investigators interested in practicing radiation oncology.”
The ASTRO-LUNGevity Resident/Fellow Seed Grant in Radiation Oncology promotes and develops the research careers of residents and fellows interested in basic, translational, and/or clinical research related to radiation oncology to benefit patients with lung cancer. This is a $25,000 one year award.
“Through this partnership with LUNGevity, ASTRO reinforces our commitment to continue to develop the radiation oncology workforce. We are delighted to partner with the LUNGevity Foundation in our support of junior investigators,” noted Dr. H. Timothy Hsiao, director of ASTRO’s Scientific Affairs Department. “We appreciate LUNGevity’s gold standard verification process, on par with the standards used by the National Institutes of Health, to ensure that the best and brightest young researchers at the forefront of radiation oncology research have a chance to establish themselves. ”
The deadline for submitting an application for the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant is March 24, 2023. The award announcement will be made in early summer 2023. For more information about this award, visit www.lungevity.org/astro-grant
About the LUNGevity Foundation
The LUNGevity Foundation is the nation’s leading lung cancer organization focused on improving outcomes for people with lung cancer. The foundation works tirelessly to advance research into earlier detection and more effective treatments, and to ensure that patients have access to these advances. LUNGevity seeks to make an immediate impact on the quality of life and survival of everyone affected by the disease – while promoting equity in health by addressing disparities across the continuum of care. LUNGevity provides information and educational tools to empower patients and their caregivers, advance impactful public policy initiatives, and amplify the patient’s voice through research and engagement. The organization provides an active community for patients and survivors – and for those who help them live better, longer lives.
Comprehensive resources include a patient-centric, clinically owned website, a free HELPLine for support, the International Lung Cancer Survival Conference, and an easy-to-use Clinical Trials Locator, among other tools. All of these programs are aimed at achieving our vision – a world where no one dies from lung cancer. The LUNGevity Foundation is proud to be a four-star Charity Navigator organization.
About lung cancer in the US
- About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime.
- More than 238,000 people in the US will be diagnosed with lung cancer this year.
- About 60% to 65% of all new lung cancer diagnoses occur among people who have never smoked or are former smokers.
- Lung cancer claims more lives in the United States than the next two deadliest cancers (colorectal and pancreatic) combined.
- Only about 23% of all people diagnosed with lung cancer in the United States will survive 5 years or more, BUT if caught before it spreads, the 5 year chance of survival increases dramatically.
Visit LUNGevity.org to learn more.
SOURCE Lungevity Foundation